- Home
- Applications
- cancerous target
Refine by
Cancerous Target Product Applications
8 applications found
The modular fashion with which Affilin® ligands can be fused together makes creating multi-specific binders an easy task. Combined with varying linker lengths, composition, and orientation, plus the optional addition of further accessory modules, our Navigo experts build the designed molecules as previously planned on the drawing ...
ByNavigo Proteins GmbH based in Halle, GERMANY
Peptides and peptidomimetics constitute excellent tumor-specific targeting moieties and can be coupled to therapeutic and diagnostic radioisotopes via a linker and a ...
By3B Pharmaceuticals GmbH based in Berlin, GERMANY
Like other nanocarriers, synthetic exosomes can be used to treat different types of cancer successfully, by encapsulating the desired anti-tumoral drug or RNA and enzymes. Several studies have used engineered exosomes from dendritic or macrophage cells to release chemotherapeutic compounds as doxorubicin, paclitaxel miRNA or siRNA to induce antitumoral activity. Rodent mammary carcinoma, mice lung cancer, glioma and pancreatic cancer are just some targeted diseases in preclinical testing using exosome delivery ...
ByNanovex Biotechnologies based in Llanera, SPAIN
Dysregulation of immune cell functions can result in many serious and fatal diseases that require re-modulating the immune cells and restoring their normal response. Monitoring of immune cells while interacting with self-cells, pathogens, and cancer promotes our understanding of immune response or its failure ...
ByTelight based in Brno, CZECH REPUBLIC
Cancer-targeted molecular probes have the potential to revolutionize surgery and diagnostics. Offering unparalleled flexibility and outstanding performance, FIRE epitomizes the cutting edge of this technology. FIRE’s quenched, substrate-based probe (qSBP) technology guides surgeons by ensuring probe signal is only seen when cancer is detected, clearly delineating tumor tissue from healthy tissue and virtually eliminating spurious background fluorescence common in other probes. ...
ByAkrotome Imaging, Inc. based in Cleveland, OHIO (USA)
A critical factor in ensuring complete resection of a solid cancer tumor is the ability to determine where diseased tissue ends and healthy tissue begins. Our research, as well as our clinical collaborators, confirm that there is a pressing unmet clinical need: the ability to rapidly and globally assess the status of marginal tissue adjacent to a tumor while the patient is in the ...
ByAkrotome Imaging, Inc. based in Cleveland, OHIO (USA)
Advances in diagnostic methods have enabled the detection of cancer at the earliest stages when the chances for successful intervention are highest. For many solid tumors, the best chance for a cure is surgery. A surgical cure depends upon the complete removal of all cancer tissue from a patient (a “complete resection”). The main challenge of this approach is that it is very difficult for a surgeon to determine where diseased tissue ends and healthy tissue begins. The result is that many surgical ...
ByAkrotome Imaging, Inc. based in Cleveland, OHIO (USA)
In many therapeutic areas, current treatments involve significant side effects. Combining drug compounds with affinity agents that target specific cell surface receptors can dramatically reduce off-target effects and improve treatment effectiveness. In several studies, aptamer-mediated drug delivery has reduced toxicity and improved drug performance. ...
ByBase Pair Biotechnologies, Inc. based in Pearland, TEXAS (USA)